Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:23:38 EDT Thu 18 Apr 2024
Enter Symbol
or Name
USA
CA



Z:MRK - MERCK & CO INC - http://www.merck.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MRK - Z0.1124.97·125.016.5125.005-0.365-0.32,653.9328,89031,801125.45  125.45  124.50133.10  99.1415:03:00Apr 0415 min RT 2¢

Recent Trades - Last 10 of 31801
Time ETExPriceChangeVolume
15:03:09Z125.0007-0.369341
15:03:08Z125.01-0.361,034
15:03:07Z124.98-0.3940
15:03:00Z125.02-0.351
15:02:56Z125.005-0.365100
15:02:56Z125.005-0.365100
15:02:54Z125.0081-0.36194
15:02:52Z125.0029-0.367175
15:02:51Z124.995-0.3754
15:02:51Z124.9912-0.3788100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-04 06:45U:MRKNews ReleaseMerck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA(TM) (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
2024-04-03 08:00U:MRKNews ReleaseREJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
2024-04-01 06:45U:MRKNews ReleaseMerck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
2024-03-28 09:18U:MRKNews ReleaseHow We Can Strengthen Vaccination Programs and Build Vaccine Confidence Together
2024-03-28 06:45U:MRKNews ReleaseEuropean Commission Approves Merck's KEYTRUDA(TM) (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
2024-03-26 18:21U:MRKNews ReleaseFDA Approves Merck's WINREVAIR(TM) (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
2024-03-26 09:32U:MRKNews ReleaseMerck Foundation Strengthens Its Commitment to Expanding Access to Care in Asia-Pacific Region
2024-03-21 06:45U:MRKNews ReleaseMerck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA(TM) (pembrolizumab) Plus Maintenance LYNPARZA(TM) (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
2024-03-19 09:00U:MRKNews ReleaseMerck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
2024-03-15 16:23U:MRKNews ReleaseFarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform
2024-03-15 06:45U:MRKNews ReleaseMerck's KEYTRUDA(TM) (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
2024-03-13 03:00U:MRKNews ReleaseMerck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL(TM)9
2024-03-11 08:15U:MRKNews ReleaseMerck Completes Acquisition of Harpoon Therapeutics, Inc.
2024-03-06 10:25U:MRKNews ReleaseGilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
2024-03-05 08:30U:MRKNews ReleaseIncreasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
2024-03-05 06:45U:MRKNews ReleaseMerck to Participate in the Barclays 26th Annual Global Healthcare Conference
2024-03-04 06:45U:MRKNews ReleaseMerck to Participate in the Leerink Partners Global Biopharma Conference 2024
2024-02-27 06:45U:MRKNews ReleaseMerck to Participate in the TD Cowen 44th Annual Health Care Conference
2024-02-23 06:20U:MRKNews ReleaseMerck Receives Positive EU CHMP Opinion for KEYTRUDA(TM) (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence
2024-02-20 06:45U:MRKNews ReleaseFDA Grants Priority Review to Merck's Application for KEYTRUDA ‚ ® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma